BioXcel Therapeutics (BTAI) Liabilities and Shareholders Equity (2017 - 2026)

BioXcel Therapeutics' Liabilities and Shareholders Equity history runs 10 years deep, the most recent figure standing at $34.0 million for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 11.77% year-over-year to $34.0 million in Q1 2026; TTM through Mar 2026 was $149.5 million, a 21.81% decrease from a year earlier, with the FY2025 full-year figure at $44.9 million, up 17.16% from the prior year.
• Liabilities and Shareholders Equity retreated to $34.0 million in Q1 2026 per BTAI's latest filing, from $44.9 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $248.2 million in Q2 2022 and bottomed at $25.8 million in Q2 2025.
• The 5-year median for Liabilities and Shareholders Equity is $73.7 million (2023), against an average of $107.5 million.
• Across the five-year window, Liabilities and Shareholders Equity sank 64.2% in 2023 and rose 17.16% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $205.9 million in 2022, then sank by 64.2% to $73.7 million in 2023, then sank by 47.98% to $38.3 million in 2024, then advanced by 17.16% to $44.9 million in 2025, then slipped by 24.25% to $34.0 million in 2026.
• Per Business Quant, the three latest BTAI Liabilities and Shareholders Equity figures stand at $34.0 million (Q1 2026), $44.9 million (Q4 2025), and $44.8 million (Q3 2025).